Parmax Pharma [PARMAX] vs Innova Captab [INNOVACAP] Detailed Stock Comparison

Parmax Pharma Ltd.

BSE
Loading...

Innova Captab Ltd.

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Parmax Pharma Ltd. wins in 5 metrics, Innova Captab Ltd. wins in 12 metrics, with 0 ties. Innova Captab Ltd. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Parmax Pharma Ltd. Innova Captab Ltd. Better
P/E Ratio (TTM) -5.63 31.20 Innova Captab Ltd.
Price-to-Book Ratio -2.43 4.05 Innova Captab Ltd.
Debt-to-Equity Ratio -2.38 32.95 Innova Captab Ltd.
PEG Ratio -0.06 1.33 Innova Captab Ltd.
EV/EBITDA 109.78 20.49 Innova Captab Ltd.
Profit Margin (TTM) 15.84% 8.85% Parmax Pharma Ltd.
Operating Margin (TTM) -6.82% 12.88% Innova Captab Ltd.
EBITDA Margin (TTM) N/A 12.88% N/A
Return on Equity 105.30% 13.37% Parmax Pharma Ltd.
Return on Assets (TTM) -11.17% 8.12% Innova Captab Ltd.
Free Cash Flow (TTM) $-16.59M $-1.09B Parmax Pharma Ltd.
Dividend Yield N/A 0.30% N/A
1-Year Return -18.44% -3.19% Innova Captab Ltd.
Price-to-Sales Ratio (TTM) 0.42 2.76 Parmax Pharma Ltd.
Enterprise Value $197.87M $43.41B Innova Captab Ltd.
EV/Revenue Ratio 0.70 2.90 Parmax Pharma Ltd.
Gross Profit Margin (TTM) 28.35% 35.19% Innova Captab Ltd.
Revenue per Share (TTM) $75 $262 Innova Captab Ltd.
Earnings per Share (Diluted) $-13.55 $23.16 Innova Captab Ltd.
Beta (Stock Volatility) N/A -0.33 N/A

Parmax Pharma Ltd. vs Innova Captab Ltd. Stock Performance Analysis

Loading Price Chart...

PARMAX
INNOVACAP

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Parmax Pharma Ltd.-10.44%37.89%57.11%56.72%48.13%51.69%
Innova Captab Ltd.-0.58%2.60%3.33%34.84%22.58%18.16%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Parmax Pharma Ltd.-18.44%19.45%-36.21%196.24%196.24%196.24%
Innova Captab Ltd.-3.19%57.07%57.07%57.07%57.07%57.07%

Performance & Financial Health Analysis: Parmax Pharma Ltd. vs Innova Captab Ltd.

MetricPARMAXINNOVACAP
Market Information
Market Cap i₹117.89M₹41.43B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i391578,151
90 Day Avg. Volume i664217,693
Last Close₹45.73₹867.50
52 Week Range₹22.60 - ₹53.38₹622.00 - ₹1,020.70
% from 52W High-14.33%-15.01%
All-Time High₹81.90 (Jun 14, 2021)₹1,260.00 (Jan 06, 2025)
% from All-Time High-44.16%-31.15%
Growth Metrics
Quarterly Revenue Growth0.71%0.42%
Quarterly Earnings Growth-0.31%0.23%
Financial Health
Profit Margin (TTM) i0.16%0.09%
Operating Margin (TTM) i-0.07%0.13%
Return on Equity (TTM) i1.05%0.13%
Debt to Equity (MRQ) i-2.3832.95
Cash & Liquidity
Book Value per Share (MRQ)₹-12.94₹178.28
Cash per Share (MRQ)N/A₹10.22
Operating Cash Flow (TTM) i₹-20,488,477₹282.88M
Levered Free Cash Flow (TTM) i₹-20,940,101₹1.28B
Dividends
Last 12-Month Dividend Yield iN/A0.30%
Last 12-Month Dividend iN/A₹2.00

Valuation & Enterprise Metrics Analysis: Parmax Pharma Ltd. vs Innova Captab Ltd.

MetricPARMAX (Apr 24, 2026)INNOVACAP (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i-5.6331.20
Forward P/E iN/A21.90
PEG Ratio i-0.061.33
Price to Sales (TTM) i0.422.76
Price to Book (MRQ) i-2.434.05
Market Capitalization
Market Capitalization i₹117.89M₹41.43B
Enterprise Value i₹197.87M₹43.41B
Enterprise Value Metrics
Enterprise to Revenue i0.702.90
Enterprise to EBITDA i109.7820.49
Risk & Other Metrics
Beta iN/A-0.33
Book Value per Share (MRQ) i₹-12.94₹178.28

Financial Statements Comparison: Parmax Pharma Ltd. vs Innova Captab Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricPARMAX (2025)INNOVACAP (2025)
Revenue/Sales i282.04M12.34B
Cost of Goods Sold i237.36M8.38B
COGS % of Revenue i84.2%67.9%
Gross Profit i44.68M3.96B
Gross Margin i15.8%32.1%
Research & Development iN/AN/A
Operating Income (EBIT) i-7.77M1.65B
Operating Margin i-2.8%13.4%
EBITDA i1.80M2.00B
EBITDA Margin i0.6%16.2%
Pre-Tax Income i-23.95M1.71B
Pre-Tax Income % of Revenue i-8.5%13.9%
Income Tax i-3.01M427.58M
Income Tax % of Revenue i-1.1%3.5%
Net Income (Profit) i-20.94M1.28B
Profit Margin i-7.4%10.4%

Balance Sheet & Liquidity Metrics

MetricPARMAX (2025)INNOVACAP (2025)
Cash & Equivalents i903,279155.19M
Total Current Assets i100.03M7.03B
Total Current Assets % of Revenue i35.5%57.0%
Total Current Liabilities i130.37M3.53B
Total Current Liabilities % of Revenue i46.2%28.6%
Long-Term Debt i77.04M2.45B
Long-Term Debt % of Revenue i27.3%19.8%
Total Shareholders Equity i-19.89M9.59B
Retained Earnings i-64.40M4.53B
Retained Earnings % of Revenue i-22.8%36.7%
Property, Plant & Equipment i17.29M442.93M

Cash Flow Statement Comparison

MetricPARMAX (2025)INNOVACAP (2025)
Operating Cash Flow i-20.49M282.88M
Operating Cash Flow % of Revenue i-7.3%2.3%
Capital Expenditures i-7.01M-1.72B
Free Cash Flow i-16.59M-1.09B
FCF Margin i-5.9%-8.8%
Debt Repayment iN/A-114.03M
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricPARMAXINNOVACAP
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i3.74M57.22M
Float Shares iN/A15.91M
% Held by Insiders i64.25%72.19%
% Held by Institutions i0.00%19.22%
% Held by Public i35.75%8.59%

Dividend Analysis & Yield Comparison: Parmax Pharma Ltd. vs Innova Captab Ltd.

MetricPARMAXINNOVACAP
Last 12-Month Dividend iN/A₹2.00
Last 12-Month Dividend Yield iN/A0.30%
3-Year Avg Annual Dividend iN/A₹0.67
3-Year Avg Dividend Yield iN/A0.30%
3-Year Total Dividends iN/A₹2.00
Ex-Dividend DateN/AJan 30, 2026